Inhibrx Biosciences, Inc. – NASDAQ:INBX
Founder-led company
Inhibrx Biosciences stock price today
$23
+7.99
+53.23%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Inhibrx Biosciences stock price monthly change
+12.94%
month
Inhibrx Biosciences stock price quarterly change
+12.94%
quarter
Inhibrx Biosciences stock price yearly change
-56.43%
year
Inhibrx Biosciences key metrics
Market Cap | 213.08M |
Enterprise value | 22.78M |
P/E | 0.14 |
EV/Sales | 13.14 |
EV/EBITDA | 0.01 |
Price/Sales | 125.30 |
Price/Book | 1.30 |
PEG ratio | N/A |
EPS | -5.35 |
Revenue | N/A |
EBITDA | -246.13M |
Income | -271.15M |
Revenue Q/Q | -100% |
Revenue Y/Y | 39.29% |
Profit margin | 94684.72% |
Oper. margin | -21326.93% |
Gross margin | 34.66% |
EBIT margin | -21326.93% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeInhibrx Biosciences stock price history
Inhibrx Biosciences stock forecast
Inhibrx Biosciences financial statements
| Jun 2023 | 30K | -47.05M | -156840% |
|---|---|---|---|
| Sep 2023 | 119K | -51.78M | -43520.17% |
| Dec 2023 | 1.63M | -93.60M | -5728.52% |
| Mar 2024 | 0 | -78.71M |
| Dec 2023 | 1.63M | -93.60M | -5728.52% |
|---|---|---|---|
| Mar 2024 | 0 | -78.71M | |
| Oct 2025 | 887K | -85.64M | -9656.12% |
| Dec 2025 | 1.10M | -88.92M | -8025.54% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 213170000 | 237.98M | 111.64% |
|---|---|---|---|
| Sep 2023 | 372733000 | 243.13M | 65.23% |
| Dec 2023 | 307893000 | 264.39M | 85.87% |
| Mar 2024 | 288577000 | 277.00M | 95.99% |
| Jun 2023 | -42.29M | -317K | 854K |
|---|---|---|---|
| Sep 2023 | -54.24M | -811K | 199.89M |
| Dec 2023 | -56.82M | -3.44M | 860K |
| Mar 2024 | -63.05M | -1.11M | 38.72M |
Inhibrx Biosciences alternative data
| Aug 2023 | 132 |
|---|---|
| Sep 2023 | 132 |
| Oct 2023 | 132 |
| Nov 2023 | 132 |
| Dec 2023 | 132 |
| Jan 2024 | 132 |
| Feb 2024 | 132 |
| Mar 2024 | 166 |
| Apr 2024 | 166 |
| May 2024 | 166 |
| Jun 2024 | 166 |
| Jul 2024 | 166 |
Inhibrx Biosciences other data
27.29%
-64.92%
of INBX is owned by hedge funds
53
-61
10.94M
-25.08M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| May 2024 | 0 | 300000 |
| Sep 2024 | 90636 | 0 |
| Oct 2024 | 6667 | 0 |
| Nov 2024 | 53593 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | KAYYEM JON FAIZ director | Common Stock | 18,750 | $14.19 | $266,100 | ||
Purchase | KAYYEM JON FAIZ director | Common Stock | 34,843 | $14.23 | $495,711 | ||
Purchase | VUORI KRISTIINA MD director | Common Stock | 6,667 | $15 | $100,005 | ||
Purchase | LAPPE MARK director, officer.. | Common Stock | 13,037 | $17.13 | $223,324 | ||
Purchase | LAPPE MARK director, officer.. | Common Stock | 26,963 | $15.05 | $405,793 | ||
Purchase | VUORI KRISTIINA MD director | Common Stock | 6,457 | $15.07 | $97,307 | ||
Purchase | VUORI KRISTIINA MD director | Common Stock | 179 | $15 | $2,685 | ||
Purchase | LAPPE MARK director, officer.. | Common Stock | 8,500 | $15.19 | $129,115 | ||
Purchase | LAPPE MARK director, officer.. | Common Stock | 9,500 | $15.21 | $144,495 | ||
Purchase | LAPPE MARK director, officer.. | Common Stock | 26,000 | $15.29 | $397,540 |
| Patent |
|---|
Grant Filling date: 1 May 2020 Issue date: 6 Sep 2022 |
Application Filling date: 11 Nov 2021 Issue date: 26 May 2022 |
Application Filling date: 10 Aug 2021 Issue date: 7 Apr 2022 |
Application Filling date: 6 Jan 2020 Issue date: 24 Mar 2022 |
Application Filling date: 5 Aug 2021 Issue date: 3 Mar 2022 |
Grant Filling date: 11 Oct 2019 Issue date: 28 Dec 2021 |
Application Filling date: 9 Oct 2019 Issue date: 9 Dec 2021 |
Application Filling date: 8 Feb 2021 Issue date: 14 Oct 2021 |
Grant Utility: Multivalent and multispecific DR5-binding fusion proteins and methods of treating neoplasms Filling date: 18 Apr 2019 Issue date: 14 Sep 2021 |
Grant Filling date: 7 Mar 2019 Issue date: 14 Sep 2021 |
-
What's the price of Inhibrx Biosciences stock today?
One share of Inhibrx Biosciences stock can currently be purchased for approximately $23.
-
When is Inhibrx Biosciences's next earnings date?
Unfortunately, Inhibrx Biosciences's (INBX) next earnings date is currently unknown.
-
Does Inhibrx Biosciences pay dividends?
Yes, Inhibrx Biosciences pays dividends and its trailing 12-month yield is 5.66% with 0% payout ratio. The last Inhibrx Biosciences stock dividend of undefined was paid on 5 Sep 2025.
-
How much money does Inhibrx Biosciences make?
Inhibrx Biosciences has a market capitalization of 213.08M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 17.36% to 1.8M US dollars.
-
What is Inhibrx Biosciences's stock symbol?
Inhibrx Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "INBX".
-
What is Inhibrx Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Inhibrx Biosciences?
Shares of Inhibrx Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Inhibrx Biosciences's key executives?
Inhibrx Biosciences's management team includes the following people:
- Mr. Mark Paul Lappe Founder, Chairman, Pres & Chief Executive Officer(age: 57, pay: $868,960)
- Dr. Klaus W. Wagner Chief Medical Officer & Executive Vice President(age: 52, pay: $600,070)
- Dr. Brendan P. Eckelman Ph.D. Founder, Chief Scientific Officer & Executive Vice President of Corporation Strategy(age: 46, pay: $589,750)
-
Is Inhibrx Biosciences founder-led company?
Yes, Inhibrx Biosciences is a company led by its founders Mr. Mark Paul Lappe and Dr. Brendan P. Eckelman Ph.D..
-
How many employees does Inhibrx Biosciences have?
As Jul 2024, Inhibrx Biosciences employs 166 workers.
-
When Inhibrx Biosciences went public?
Inhibrx Biosciences, Inc. is publicly traded company for just a year since IPO on 4 Jun 2024.
-
What is Inhibrx Biosciences's official website?
The official website for Inhibrx Biosciences is inhibrx.com.
-
Where are Inhibrx Biosciences's headquarters?
Inhibrx Biosciences is headquartered at 11025 North Torrey Pines Road, La Jolla, CA.
-
How can i contact Inhibrx Biosciences?
Inhibrx Biosciences's mailing address is 11025 North Torrey Pines Road, La Jolla, CA and company can be reached via phone at 858-795-4220.
Inhibrx Biosciences company profile:
Inhibrx Biosciences, Inc.
inhibrx.comExchange:
NASDAQ
Full time employees:
166
Industry:
Biotechnology
Sector:
Healthcare
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candidate targeting death-receptor 5 that is in phase 2 clinical trial for the treatment of unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 that is in phase 2 clinical trial for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head and neck cancer, gastric (GIST) and gastroesophageal adenocarcinoma (GEA) cancer, renal cell carcinoma, and urothelial (transitional) cell carcinoma. The company was incorporated in 2024 and is based in La Jolla, California.
11025 North Torrey Pines Road
La Jolla, CA 92037
La Jolla, CA 92037
CIK: 0001739614
ISIN: US45720L1070
CUSIP: 45720L107
